Thrombosis prophylaxis and mortality risk among critically Ill adults

Chest

Volumn 146, Issue 1, 2014, Pages 51-57

  Lilly, Craig M ^a   Liu, Xinggang ^a   Badawi, Omar ^b   Franey, Christine S ^a,c   Zuckerman, Ilene H ^a,d  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b University of Massachusetts Medical School ^*  (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d PHILIPS HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; TINZAPARIN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; APACHE; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; COMPRESSION BOOTS; COMPRESSION STOCKING; CONTROLLED STUDY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DYING; FEMALE; GENERAL DEVICE; HAZARD RATIO; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CODING; PRIORITY JOURNAL; THROMBOSIS PREVENTION; TREATMENT CONTRAINDICATION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CRITICAL ILLNESS; FEMALE; HOSPITAL MORTALITY; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROGNOSIS; RESPIRATION, ARTIFICIAL; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84903835648     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2160     Document Type: Article

References (19)

1. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidencebased clinical practice guidelines. Chest. 2012;141(2-suppl):e195S-e226S.
2. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988; 318 (18): 1162-1173.
3. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. Executive summary: antithrombotic therapy and preven tion of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2-suppl):7S-47S.
4. Spyropoulos AC, Anderson FA Jr, Fitzgerald G, et al; IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011; 140 (3): 706-714.
5. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007; 146 (4): 278-288.
6. Lloyd NS, Douketis JD, Moinuddin I, Lim W, Crowther MA. Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis. J Th romb Haemost. 2008; 6 (3): 405-414.
7. Alikhan R, Cohen AT. Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database Syst Rev. 2009;(3): CD003747.
8. Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF; LIFENOX Investigators. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011; 365 (26): 2463-2472.
9. McShea M, Holl R, Badawi O, Riker RR, Silfen E. The eICU Research Institute - a collaboration between industry, healthcare providers, and academia. IEEE Eng Med Biol Mag. 2010; 29 (2): 18-25.
10. Lilly CM, Zuckerman IH, Badawi O, Riker RR. Benchmark data from more than 240,000 adults that refl ect the current practice of critical care in the United States. Chest. 2011; 140 (5): 1232-1242.
11. Imbens GW. The role of the propensity score in estimating dose-response functions. Biometrika. 2000; 87 (3): 706-710.
12. Foster EM. Propensity score matching: an illustrative analysis of dose response. Med Care. 2003; 41 (10): 1183-1192.
13. Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc. 1999; 94 (446): 496-509.
14. Eppsteiner RW, Shin JJ, Johnson J, van Dam RM. Mechanical compression versus subcutaneous heparin therapy in postoperative and posttrauma patients: a systematic review and meta-analysis. World J Surg. 2010; 34 (1): 10-19.
15. Dennis M, Sandercock P, Reid J, Graham C, Forbes J, Murray G; CLOTS (Clots in Legs Or sTockings aft er Stroke) Trials Collaboration. Eff ectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet. 2013; 382 (9891): 516-524.
16. Comerota AJ, Katz ML, White JV. Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am J Surg. 1992; 164 (3): 265-268.
17. Cornwell EE III, Chang D, Velmahos G, et al. Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. Am Surg. 2002; 68 (5): 470-473.
18. Cook D, Meade M, Guyatt G, et al; PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011; 364 (14): 1305-1314.
19. Kearon C, Akl EA, Comerota AJ. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2-suppl):e419S-e494S.